You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCodeine
Accession NumberDB00318  (APRD00120, DB09471)
TypeSmall Molecule
GroupsApproved, Illicit
DescriptionAn opioid analgesic related to morphine but with less potent analgesic properties and mild sedative effects. It also acts centrally to suppress cough. [PubChem]
Structure
Thumb
Synonyms
(−)-Codeine
(5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol
(5α,6α)-7,8-didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol
3-Methylmorphin
3-methylmorphine
7,8-didehydro-4,5alpha-epoxy-3-methoxy-17-methylmorphinan-6alpha-ol
7,8-didehydro-4,5α-epoxy-3-methoxy-17-methylmorphinan-6α-ol
Codein
Codeína
Codéine
Codeine anhydrous
Codeinum
L-Codeine
Methylmorphine
morphine 3-methyl ether
Morphine monomethyl ether
morphine monomethyl ether
morphine-3-methyl ether
O(3)-methylmorphine
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Codeine 15Tablet15 mgOralLaboratoire Riva Inc1994-12-31Not applicableCanada
Codeine 30Tablet30 mgOralLaboratoire Riva Inc1994-12-31Not applicableCanada
Codeine Contin 100mg Controlled Release TabTablet, extended release100 mgOralPurdue Pharma1995-12-31Not applicableCanada
Codeine Contin 150mg Controlled Release TabTablet, extended release150 mgOralPurdue Pharma1995-12-31Not applicableCanada
Codeine Contin 200mg Controlled Release TabTablet, extended release200 mgOralPurdue Pharma1995-12-31Not applicableCanada
Codeine Contin 50mg Controlled Release TabTablet, extended release50 mgOralPurdue Pharma1997-03-13Not applicableCanada
Codeine Phosphate Inj 30mg/mlSolution30 mgIntramuscular; SubcutaneousHospira Healthcare Corporation1981-12-31Not applicableCanada
Codeine Phosphate Inj 60mg/mlSolution60 mgIntramuscular; SubcutaneousHospira Healthcare Corporation1981-12-31Not applicableCanada
Codeine Phosphate Injection USPLiquid30 mgIntramuscular; SubcutaneousSandoz Canada Incorporated1978-12-31Not applicableCanada
Codeine Phosphate SyrupSyrup5 mgOralD.C. Labs Limited1951-12-312005-07-19Canada
Codeine Phosphate SyrupSyrup5.0 mgOralLaboratoire Atlas Inc1986-12-18Not applicableCanada
Codeine Phosphate Tab 15mgTablet15 mgOralD.C. Labs Limited1951-12-312003-07-11Canada
Codeine Phosphate Tab 30mgTablet30 mgOralD.C. Labs Limited1951-12-312003-07-11Canada
Codeine Phosphate Tab 60mgTablet60 mgOralD.C. Labs Limited1951-12-312003-07-11Canada
Codeine SulfateSolution30 mg/5mLOralTAGI Pharma, Inc.2012-06-012017-01-07Us
Codeine SulfateTablet60 mg/1OralWest Ward Pharmaceuticals Corp.2009-07-16Not applicableUs
Codeine SulfateTablet60 mg/1OralPhysicians Total Care, Inc.2009-07-15Not applicableUs
Codeine SulfateSolution15 mg/2.5mLOralPrecision Dose Inc.2013-02-252016-01-16Us
Codeine SulfateTablet15 mg/1OralWest Ward Pharmaceuticals Corp.2009-07-16Not applicableUs
Codeine SulfateSolution30 mg/5mLOralPrecision Dose Inc.2013-02-262016-01-16Us
Codeine SulfateTablet30 mg/1OralWest Ward Pharmaceuticals Corp.2009-07-16Not applicableUs
Codeine Tab 15mgTablet15 mgOralRougier Pharma Division Of Ratiopharm Inc1951-12-312015-10-01Canada
Codeine Tab 30mgTablet30 mgOralRougier Pharma Division Of Ratiopharm Inc1951-12-311999-09-27Canada
Linctus Codeine BlancLiquid.2 %OralLaboratoire Atlas Inc1978-12-31Not applicableCanada
Paveral Liq 10mg/mlLiquid10 mgOralRougier Pharma Division Of Ratiopharm Inc1990-12-311999-09-27Canada
PMS-codeineTablet30 mgOralPharmascience Inc2001-12-16Not applicableCanada
PMS-codeineTablet15 mgOralPharmascience Inc2001-11-16Not applicableCanada
Ratio-codeineSyrup5 mgOralTeva Canada Limited1977-12-31Not applicableCanada
Ratio-codeineTablet15 mgOralTeva Canada Limited1983-12-31Not applicableCanada
Ratio-codeineTablet30 mgOralTeva Canada Limited1983-12-31Not applicableCanada
Stanley Syrup W Codeine PhosphateSyrup5 mgOralStanley Pharmaceuticals, A Division Of Vita Health Products Inc.1965-12-311997-08-08Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Acetaminophen and Codeine PhosphateTablet300 mg/1OralREMEDYREPACK INC.2013-04-04Not applicableUs
Codeine SulfateTablet30 mg/1OralLannett Company, Inc.2014-06-13Not applicableUs
Codeine SulfateTablet60 mg/1OralLannett Company, Inc.2014-06-13Not applicableUs
Codeine SulfateTablet15 mg/1OralLannett Company, Inc.2014-06-13Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ActacodeSigma
BisoltusBoehringer Ingelheim
BromopharQualiphar
BronchicumSanofi-Aventis
BronchodinePharmacobel
CodantAntigen
CodedrillPierre Fabre
CodeinCristália
CodeisanBelmac
CoderpinaFrycia Centro América
CodicalmWelti
CodiceptNot Available
CodinexPinewood
CoduceptNot Available
CougelHwang's
CoutanMey See
DincoCenter
FarmacodFarmacom
GalcodineThornton & Ross
PectoralSiphat
TussoretMaxMedic
Brand mixtures
NameLabellerIngredients
(extra Strength) Acetaminophen, Caffeine & 8mg Codeine Phosphate CapletsStanley Pharmaceuticals, A Division Of Vita Health Products Inc.
222 TabletsMcneil Consumer Healthcare Division Of Johnson & Johnson Inc
282 Mep TabMerck Frosst Canada & Cie, Merck Frosst Canada & Co.
282 TabMerck Frosst Canada & Cie, Merck Frosst Canada & Co.
282 TabletsPendopharm Division Of De Pharmascience Inc
292 TabMerck Frosst Canada & Cie, Merck Frosst Canada & Co.
292 TabletsPendopharm Division Of De Pharmascience Inc
A & C Tablets With Codeine 15mgD.C. Labs Limited
A & C Tablets With Codeine 30mgD.C. Labs Limited
A.C. & C 8mg TabVita Health Products Inc
A.C. & C. 8 mgLaboratoires Confab Inc
A.C. & C. 8mgWestcan Pharmaceuticals Ltd.
A.C.& C TabletsPharmascience Inc
Ac and C Tab 1/8grPharmascience Inc
Ac&c TabletsPharmascience Inc
Acet 2Pharmascience Inc
Acet 3Pharmascience Inc
Acet Codeine 30 TabPharmascience Inc
Acet Codeine 60 TabPharmascience Inc
Acetaminophen 300 Mg With 15 Mg Caffeine and 8 Mg Codeine PhosphateVita Health Products Inc
Acetaminophen 300mg, Caffeine & CodeineTanta Pharmaceuticals Inc
Acetaminophen 325 C & CTechnilab Pharma Inc.
Acetaminophen 325 Mg Caffeine and CodeineTanta Pharmaceuticals Inc
Acetaminophen 325 Mg With 15 Mg Caffeine and 8 Mg Codeine PhosphateVita Health Products Inc
Acetaminophen 500 Mg Compound Tablets With CodeinePharmascience Inc
Acetaminophen 500 Mg With 15 Mg Caffeine and 8 Mg Codeine PhosphateVita Health Products Inc
Acetaminophen 500mg, Caffeine and 8mg Codeine PhosphatePharmetics (2011) Inc
Acetaminophen and CodeineLiberty Pharmaceuticals, Inc.
Acetaminophen and Codeine PhosphatePharmaceutical Associates, Inc.
Acetaminophen Caffeine & 8mg Cod Phos TabStanley Pharmaceuticals, A Division Of Vita Health Products Inc.
Acetaminophen Caffeine & 8mg Cod. Phos. TabNovopharm Limited
Acetaminophen Compound Tablets With Codeine 8mgD.C. Labs Limited
Acetaminophen Elixir With 8mg Codeine Phosphate SyrupJamp Pharma Corporation
Acetaminophen W Codeine TabPharmascience Inc
Acetaminophen With CodeinePharm Pak, Inc.
Acetaminophen With Codeine - CapletTeva Canada Limited
Acetaminophen-caffeine-codeineLaboratoires Confab Inc
Acetaminophen, Caffeine & 8mg Codeine PhosphatePharmascience Inc
Acetaminophen, Caffeine & 8mg Codeine Phosphate TabletsJamp Pharma Corporation
Acetaminophen, Caffeine & CodeinePharmascience Inc
Acetaminophen, Caffeine & Codeine TabletsPharmascience Inc
Acetaminophen, Caffeine and 8 Mg Of Codeine Phosphate TabletsPharmetics (2011) Inc
Acetaminophen, Caffeine, and 8mg Of Codeine Phosphate TabletsPharmetics (2011) Inc
Acetaminophene Codeine Et Cafeine CapletsLaboratoire Riva Inc
Acetaminophene Codeine Et Cafeine FortLaboratoires Trianon Inc
Acetazone Forte C8Teva Canada Limited
Acetylsalicylic Acid, Caffeine & 8 Mg Codeine Phosphate TabletsJamp Pharma Corporation
Acetylsalicylic Acid, Caffeine and 8mg Codeine PhosphatePharmetics (2011) Inc
AiracofCenturion Labs, Llc
Ala-hist AcPoly Pharmaceuticals
Anacin With Codeine TabWhitehall Robins Inc.
Apo-acetaco #1Apotex Inc
Asa-caffeine-codeineLaboratoires Confab Inc
Asa, Caffeine & 8mg Codeine PhosphateCanapharm Manufacturing Inc
Ascomp With CodeineNexgen Pharma, Inc.
Atasol 15 TabChurch & Dwight Canada Corp
Atasol 30 TabChurch & Dwight Canada Corp
Atasol 8 TabChurch & Dwight Canada Corp
Axacet-C1/8Technilab Pharma Inc.
Axisal-C1/8Technilab Pharma Inc.
Balminil Codeine + Decongestant + ExpectorantRougier Pharma Division Of Ratiopharm Inc
Balminil Codeine Night Time + ExpectorantRougier Pharma Division Of Ratiopharm Inc
Benylin 2 Cold and Flu With CodeineMcneil Consumer Healthcare Division Of Johnson & Johnson Inc
Benylin Codeine 3.3mg De SyrPfizer Canada Inc., Consumer Healthcare Division
Butalbital, Acetaminophen and Caffeine With Codeine PhosphateWest Ward Pharmaceuticals Corp
Butalbital, Acetaminophen, Caffeine and Codeine PhosphateBreckenridge Pharmaceutical, Inc.
Butalbital, Acetaminophen, Caffeine, and Codeine PhosphateActavis Pharma, Inc.
Butalbital, Aspirin, Caffeine and Codeine PhosphateLannett Company, Inc.
Butalbital, Aspirin, Caffeine, and Codeine PhosphateMayne Pharma Inc.
C T Acetylsalicylic Acid Codeine and Caf TabPharmavite Laboratories (1987) Inc.
C-2 Buffered With CodeinePharmascience Inc
C2 Buffered With Codeine TabWampole Brands, A Division Of Pangeo Pharma (Canada) Inc.
C2 Tab With CodeineWampole Brands, A Division Of Pangeo Pharma (Canada) Inc.
CalmylinTeva Canada Limited
Calmylin AceTeva Canada Limited
Calmylin Codeine D-E SyrTechnilab Pharma Inc.
Calmylin Pse With CodeineTeva Canada Limited
CapcofCapital Pharmaceutical, Llc
Capital and CodeineValeant Pharmaceuticals International
Carisoprodol, Aspirin and Codeine PhosphateEon Labs, Inc.
Cheracol Cough SyrupShire Pharma Canada Ulc
Cheratussin AcQualitest Pharmaceuticals
Cheratussin DacQualitest Pharmaceuticals
CoactifedGlaxosmithkline Inc
Codar ArRespa Pharmaceuticals, Inc.
Codar DRespa Pharmaceuticals
Codar GfRespa Pharmaceuticals, Inc.
Codeine and Chlorpheniramine Maleate ERNexgen Pharma, Inc.
Codeine-guaifenesinMethod Pharmaceuticals, Llc
Coditussin AcGlendale Inc
Coditussin DacGlendale Inc
Coryphen 325 Codeine 30 TabRougier Pharma Division Of Ratiopharm Inc
Coryphen 650 Codeine 30 TabRougier Pharma Division Of Ratiopharm Inc
CotabsPharmavite Laboratories (1987) Inc.
CotrifedTechnilab Pharma Inc.
Cough Syr W Codeine Diphenhyd HCl & Ammon ClStanley Pharmaceuticals, A Division Of Vita Health Products Inc.
Cough Syr W.cod. Pseudoephed.hcl GuaifenesinStanley Pharmaceuticals, A Division Of Vita Health Products Inc.
Cough SyrupTeva Canada Limited
Cough Syrup With CodeineTeva Canada Limited
Covan SyrupPharmascience Inc
Damylin Avec Codeine SiropLaboratoire Atlas Inc
Damylin With Codeine SyrupLaboratoire Riva Inc
Dimetane Expectorant CPfizer Consumer Healthcare A Division Of Pfizer Canada Inc
Dimetane Expectorant-C SyrWhitehall Robins Inc.
Dimetapp-CPfizer Consumer Healthcare A Division Of Pfizer Canada Inc
Dimetapp-C SyrWhitehall Robins Inc.
Empracet-30Glaxosmithkline Inc
Empracet-60Glaxosmithkline Inc
Endacof CLarken Laboratories, Inc.
Exdol 15tabMerck Frosst Canada & Cie, Merck Frosst Canada & Co.
Exdol 30tabMerck Frosst Canada & Cie, Merck Frosst Canada & Co.
Exdol 8 TabMerck Frosst Canada & Cie, Merck Frosst Canada & Co.
Exdol-15Pharmascience Inc
Exdol-30Pharmascience Inc
Exdol-8Pharmascience Inc
Execlear CLarken Laboratories, Inc.
Fioricet With CodeineWatson Pharma, Inc.
Fiorinal C1/2Tribute Pharmaceuticals Canada Inc
Fiorinal C1/4Tribute Pharmaceuticals Canada Inc
Fiorinal With CodeineActavis Pharma, Inc.
Guaiatussin AcHi Tech Pharmacal Co., Inc.
Guaifenesin AcRising Pharmaceuticals
Guaifenesin and Codeine PhosphatePharmaceutical Associates, Inc.
Guaifenesin and Codeine Phosphate SfPhysicians Total Care, Inc.
Guaifenesin DacRising Pharmaceuticals
Histex AcAllegis Pharmaceuticals, LLC
Iophen C NrQualitest Pharmaceuticals
Lexuss 210Centurion Labs
Lortuss EXSallus Laboratories, Llc
M-clear WcR.A. Mc Neil Company
M-end Max DR.A. Mc Neil Company
M-end PER.A. Mc Neil Company
M-end WcR.A. Mc Neil Company
Mar-cof BPMarnel Pharmaceutcals, Inc.
Mar-cof Cg ExpectorantMarnel Pharmaceutcals, Inc.
Mersyndol With CodeineSanofi Aventis Canada Inc
Methoxacet-C 1/8Teva Canada Limited
Methoxisal-C 1/2Teva Canada Limited
Methoxisal-C 1/4Teva Canada Limited
Methoxisal-C 1/8Teva Canada Limited
Muscle & Back Pain Relief - 8Vita Health Products Inc
Muscle & Back Pain Relief-8Pharmascience Inc
Muscle and Back Pain Relief - 8 TabletsPharmetics (2011) Inc
Muscle and Back Pain Relief CapletsJamp Pharma Corporation
Muscle and Back Pain Relief-8Teva Canada Limited
Neo AcLaser Pharmaceuticals Llc
Ninjacof-XGCenturion Labs, Llc
Notuss PESj Pharmaceuticals, Llc
Notuss-NXSj Pharmaceuticals, Llc
Notuss-nxdSj Pharmaceuticals, Llc
Novahistex CAventis Pharma Inc
Novo Ac and C 8mg TabNovopharm Limited
Novo-gesic C15Novopharm Limited
Novo-gesic C30Novopharm Limited
Novo-gesic-C8Novopharm Limited
Nu-acetaco #1Nu Pharm Inc
Oradrine TabletsPharmavite Laboratories (1987) Inc.
Painex Tab 0.25grIcn Canada Ltd.
Painex Tab 0.5grIcn Canada Ltd.
Parafon Forte C8 W Codeine TabMcneil Pharmaceutical, Division Of Ortho Mcneil Inc.
Pentuss SrsRhone Poulenc Rorer Canada Inc.
Phenaphen No 2 CapAyerst Laboratories
Phenaphen No 3 CapAyerst Laboratories
Phenaphen No 4 CapAyerst Laboratories
Phenaphen No.2 CapWyeth Ayerst Canada Inc.
Phenaphen No.3 CapWyeth Ayerst Canada Inc.
Phenaphen No.4 CapWyeth Ayerst Canada Inc.
Phenylhistine DhQualitest Pharmaceuticals
PHL-acet-codeine 30Pharmel Inc
PHL-acet-codeine 60Pharmel Inc
PluratussCreekwood Pharmaceutical, Inc.
PMS-acetaminophen W Codeine ElixirPharmascience Inc
PMS-pharnal-C 1/4 CapsulesPharmascience Inc
PMS-pharnal-C1/2 CapsulesPharmascience Inc
Poly Hist NcPoly Pharmaceuticals, Inc.
Poly-tussinPoly Pharmaceuticals
Poly-tussin AcPoly Pharmaceuticals, Inc.
Poly-tussin DPoly Pharmaceuticals
Pracet 30Laboratoire Riva Inc
Pro-clear AcPro Pharma Llc
Pro-red AcPro Pharma, Llc
Procet-30Pro Doc Limitee
Prometh With CodeineActavis Mid Atlantic LLC
Promethazine HCl, Phenylephrine HCl, Codeine PhosphateAmneal Pharmaceuticals of New York, LLC
Promethazine Hydrochloride and Codeine PhosphatePharmaceutical Associates, Inc.
Promethazine Hydrochloride Phenylephrine Hydrochloride and Codeine Phosphatebryant ranch prepack
Promethazine Hydrochloride, Phenylephrine Hydrochloride, and Codeine PhosphateHi Tech Pharmacal Co., Inc.
Promethazine Vc With CodeineActavis Mid Atlantic LLC
Promethazine With CodeineQualitest Pharmaceuticals
Promethazine With Codeine CoughMorton Grove Pharmaceuticals, Inc.
Pronal - C1/2 CapsulesPro Doc Limitee
Pronal C1/4 CapsulesPro Doc Limitee
Ratio-cotridinTeva Canada Limited
Ratio-cotridin ExpectorantTeva Canada Limited
Ratio-emtec-30Teva Canada Limited
Ratio-lenoltec No 1Teva Canada Limited
Ratio-lenoltec No 2Teva Canada Limited
Ratio-lenoltec No 3Teva Canada Limited
Ratio-lenoltec No 4Teva Canada Limited
Ratio-tecnal C 1/2Teva Canada Limited
Ratio-tecnal C 1/4Teva Canada Limited
Relcof-CBurel Pharmaceuticals, Llc
Robafen AcMajor Pharmaceuticals
Robaxacet-8Pfizer Consumer Healthcare A Division Of Pfizer Canada Inc
Robaxisal C 1/2Pfizer Consumer Healthcare A Division Of Pfizer Canada Inc
Robaxisal C 1/4Pfizer Consumer Healthcare A Division Of Pfizer Canada Inc
Robaxisal C-1/8 TabletsWyeth Consumer Healthcare Inc.
Robitussin AcPfizer Consumer Healthcare A Division Of Pfizer Canada Inc
Robitussin Syrup With CodeineWyeth Consumer Healthcare Inc.
Rounox Avec Codeine 15tabRougier Pharma Division Of Ratiopharm Inc
Rounox Codeine 30 TabRougier Pharma Division Of Ratiopharm Inc
Rounox Codeine 60 TabRougier Pharma Division Of Ratiopharm Inc
Routec and Codeine 30 - TabRougier Pharma Division Of Ratiopharm Inc
RydexCenturion Labs
Sinutab With Codeine TabletsMcneil Consumer Healthcare Division Of Johnson & Johnson Inc
Spasmhalt-8Pendopharm Division Of De Pharmascience Inc
Spasmhalt-asa-8Pendopharm Division Of De Pharmascience Inc
Statuss GreenMagna Pharmaceuticals, Inc.
Suppress Cough Syr W.cod.diphen.hcl Amm.chl.Stanley Pharmaceuticals, A Division Of Vita Health Products Inc.
Tamicode TabletsViva Pharmaceutical Inc.
Theracodeine-300Physician Therapeutics Llc
Triacin-CSTI Pharma LLC
Trianal C½Laboratoire Riva Inc
Trianal C¼Laboratoire Riva Inc
Triatec-30Laboratoire Riva Inc
Triatec-8Laboratoire Riva Inc
Triatec-8 FortLaboratoire Riva Inc
Tricode ArRespa Pharmaceuticals, Inc.
Tricode GfRespa Pharmaceuticals, Inc.
Tusnel CLlorens Pharmaceutical International Division
Tussaminic C Forte SyrupNovartis Consumer Health Canada Inc.
Tussaminic C Pediatric SyrupNovartis Consumer Health Canada Inc.
Tylenol No 1 TabMcneil Pharmaceutical, Division Of Ortho Mcneil Inc.
Tylenol No.1 CapletsMcneil Consumer Healthcare Division Of Johnson & Johnson Inc
Tylenol No.1 Forte CapletsMcneil Consumer Healthcare Division Of Johnson & Johnson Inc
Tylenol No1 Forte Tablets With CodeineMcneil Pharmaceutical, Division Of Ortho Mcneil Inc.
Tylenol W Codeine No2 TabMcneil Pharmaceutical, Division Of Ortho Mcneil Inc.
Tylenol W Codeine No3 TabMcneil Pharmaceutical, Division Of Ortho Mcneil Inc.
Tylenol W Codeine No4 TabMcneil Pharmaceutical, Division Of Ortho Mcneil Inc.
Tylenol With CodeineA S Medication Solutions Llc
Tylenol With Codeine ElixirJanssen Inc
Tylenol With Codeine No. 2 - TabJanssen Inc
Tylenol With Codeine No. 3 - TabJanssen Inc
Tylenol With Codeine No. 4 - TabJanssen Inc
Virtussin A/cVirtus Pharmaceuticals
Virtussin AcVirtus Pharmaceuticals LLC
Virtussin DacVirtus Pharmaceuticals
Wampole-acetaminophen/codeine/caffeineJamp Pharma Corporation
Z-tuss AcMagna Pharmaceuticals, Inc.
Z-tuss EMagna Pharmaceuticals, Inc.
Zodryl Ac 25Coda Dose, Inc.
Zodryl Ac 30Coda Dose, Inc.
Zodryl Ac 40Coda Dose, Inc.
Zodryl Ac 50Coda Dose, Inc.
Zodryl Ac 60Coda Dose, Inc.
Zodryl Ac 80Coda Dose, Inc.
Zodryl Dec 25Coda Dose, Inc.
Zodryl Dec 30Coda Dose, Inc.
Zodryl Dec 40Coda Dose, Inc.
Zodryl Dec 50Coda Dose, Inc.
Zodryl Dec 60Coda Dose, Inc.
Zodryl Dec 80Coda Dose, Inc.
Zotex-CVertical Pharmaceuticals, Inc.
Salts
Name/CASStructureProperties
Codeine hydrochloride
1422-07-7
Thumb
  • InChI Key: NUXLENPAZQNFAM-FFHNEAJVSA-N
  • Monoisotopic Mass: 335.1288213
  • Average Mass: 335.83
DBSALT001068
Codeine monohydrate
6059-47-8
Thumb
  • InChI Key: WRRSFOZOETZUPG-FFHNEAJVSA-N
  • Monoisotopic Mass: 317.162708225
  • Average Mass: 317.385
DBSALT001844
Codeine phosphate
52-28-8
Thumb
  • InChI Key: WUXLCJZUUHIXFY-FFHNEAJVSA-N
  • Monoisotopic Mass: 397.129038639
  • Average Mass: 397.3594
DBSALT000030
Codeine phosphate hemihydrate
41444-62-6
Thumb
  • InChI Key: DKSZLDSPXIWGFO-BLOJGBSASA-N
  • Monoisotopic Mass: 812.268642914
  • Average Mass: 812.743
DBSALT001592
Codeine sulfate
1420-53-7
Thumb
  • InChI Key: BCXHDORHMMZBBZ-DORFAMGDSA-N
  • Monoisotopic Mass: 696.271666799
  • Average Mass: 696.81
DBSALT000031
Codeine sulfate trihydrate
6854-40-6
Thumb
  • InChI Key: BOLDZXRCJAJADM-AAXBYHQXSA-N
  • Monoisotopic Mass: 750.303360852
  • Average Mass: 750.86
DBSALT001843
Categories
UNIIUX6OWY2V7J
CAS number76-57-3
WeightAverage: 299.3642
Monoisotopic: 299.152143543
Chemical FormulaC18H21NO3
InChI KeyOROGSEYTTFOCAN-DNJOTXNNSA-N
InChI
InChI=1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3-6,11-13,17,20H,7-9H2,1-2H3/t11-,12+,13-,17-,18-/m0/s1
IUPAC Name
(1S,5R,13R,14S,17R)-10-methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7(18),8,10,15-tetraen-14-ol
SMILES
[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O
Pharmacology
IndicationFor treatment and management of pain (systemic). It is also used as an antidiarrheal and as a cough suppressant.
Structured Indications
PharmacodynamicsCodeine, an opiate agonist in the CNS, is similar to other phenanthrene derivatives such as morphine. It is selective for the mu receptor, but with a much weaker affinity than morphine. The analgesic properties of codeine have been speculated to come from its conversion to morphine. The principle therapeutic action is analgesia. Codeine concentrations do not correlate with brain concentration or relief of pain. The minimum effective concentration is highly variable is influenced by numerous factors, including but not limited to, age, previous opioid use, age, and general medical condition. However, the effective dose for patients that have developed tolerance is significantly higher than the opioid-naive patients.
Mechanism of actionOpiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Codeine's analgesic activity is, most likely, due to its conversion to morphine. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability.
TargetKindPharmacological actionActionsOrganismUniProt ID
Mu-type opioid receptorProteinyes
partial agonist
HumanP35372 details
Kappa-type opioid receptorProteinyes
partial agonist
HumanP41145 details
Delta-type opioid receptorProteinyes
agonist
HumanP41143 details
Related Articles
AbsorptionWell absorbed following oral administration with a bioavailability of approximately 90%. Maximum plasma concentration occurs 60 minutes post-administration. Food does not effect the rate or extent of absorption of codeine.
Volume of distribution

Apparent volume of distribution = 3-6 L/kg

Protein binding7-25% bound to plasma proteins.
Metabolism

Hepatic. Codeine is a prodrug, itself inactive, but demethylated to the active morphine by the liver enzyme CYP2D6 to morphine. 70-80% of the dose undergoes glucuronidation to form codeine-6-glucuronide. This process is mediated by UDP-glucuronosyltransferase UGT2B7 and UGT2B4. 5-10% of the dose undergoes O-demethylation to morphine and 10% undergoes N-demethylation to form norcodeine. CYP2D6 mediates the biotransformation to morphine. CYP3A4 is the enzymes that mediates the conversion to norcodiene. Morphine and norcodeine are further metabolized and undergo glucuronidation. The glucuronide metabolites of morphine are morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G). Both morphine and morphine-6-glucuronide are active and have analgesic activity. Norcodiene and M3G do not have any analgesic properties.

SubstrateEnzymesProduct
Codeine
morphineDetails
Codeine
norcodeineDetails
Codeine
Codeine-6-glucuronideDetails
Route of elimination90% of the total dose of codeine is excreted through the kidneys, of which 10% is unchanged codeine.
Half lifePlasma half-lives of codeine and its metabolites have been reported to be approximately 3 hours.
ClearanceNot Available
ToxicityRespiratory depression, sedation and miosis and common symptoms of overdose. Other symptoms include nausea, vomiting, skeletal muscle flaccidity, bradycardia, hypotension, and cool, clammy skin. Apnea and death may ensue.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Codeine Metabolism PathwayDrug metabolismSMP00621
Codeine Action PathwayDrug actionSMP00405
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Cytochrome P450 2D6
Gene symbol: CYP2D6
UniProt: P10635
rs3892097 CYP2D6*4A Allele, homozygotePoor drug metabolizer, lower dose requirements1782973
Cytochrome P450 2D6
Gene symbol: CYP2D6
UniProt: P10635
rs5030655 CYP2D6*6T deletion, homozygotePoor drug metabolizer, lower dose requirements1782973
Cytochrome P450 2D6
Gene symbol: CYP2D6
UniProt: P10635
Not AvailableCYP2D6*5Deletion, homozygotePoor drug metabolizer, lower dose requirements1782973
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Codeine is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Codeine.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Codeine.Experimental, Illicit
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Codeine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Codeine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Codeine is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Codeine can be increased when it is combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Codeine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Codeine is combined with Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Codeine is combined with Acetazolamide.Approved, Vet Approved
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Codeine.Approved
adipiplonThe risk or severity of adverse effects can be increased when Codeine is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Codeine is combined with Agomelatine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Codeine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Codeine is combined with Alfentanil.Approved, Illicit
AlimemazineAlimemazine may increase the hypotensive activities of Codeine.Approved, Vet Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Codeine is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Codeine is combined with Alprazolam.Approved, Illicit, Investigational
AlvimopanThe risk or severity of adverse effects can be increased when Codeine is combined with Alvimopan.Approved
AmilorideThe risk or severity of adverse effects can be increased when Codeine is combined with Amiloride.Approved
AmiodaroneThe therapeutic efficacy of Codeine can be decreased when used in combination with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Codeine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Codeine is combined with Amitriptyline.Approved
Ammonium chlorideAmmonium chloride may increase the excretion rate of Codeine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Vet Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Codeine is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Codeine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Codeine is combined with Amperozide.Experimental
AmphetamineAmphetamine may increase the analgesic activities of Codeine.Approved, Illicit
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Codeine.Approved
AprepitantThe serum concentration of Codeine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Codeine.Approved, Investigational
ArtemetherThe therapeutic efficacy of Codeine can be decreased when used in combination with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Codeine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Codeine is combined with Asenapine.Approved
AtazanavirThe metabolism of Codeine can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe therapeutic efficacy of Codeine can be decreased when used in combination with Atomoxetine.Approved
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Codeine.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Codeine.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Codeine is combined with Azaperone.Vet Approved
AzelastineCodeine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Codeine is combined with Azelastine.Approved
AzosemideThe risk or severity of adverse effects can be increased when Codeine is combined with Azosemide.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Codeine is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Codeine is combined with Barbital.Illicit
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Codeine.Withdrawn
BendroflumethiazideThe risk or severity of adverse effects can be increased when Codeine is combined with Bendroflumethiazide.Approved
BenperidolThe risk or severity of adverse effects can be increased when Codeine is combined with Benperidol.Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Codeine.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Codeine is combined with Benzocaine.Approved
BenzphetamineBenzphetamine may increase the analgesic activities of Codeine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Codeine is combined with Benzyl alcohol.Approved
BetaxololThe therapeutic efficacy of Codeine can be decreased when used in combination with Betaxolol.Approved
BexaroteneThe serum concentration of Codeine can be decreased when it is combined with Bexarotene.Approved, Investigational
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Codeine.Approved
BL-1020BL-1020 may increase the hypotensive activities of Codeine.Investigational
BoceprevirThe metabolism of Codeine can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Codeine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Codeine can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Codeine is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Codeine is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Codeine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Codeine is combined with Bromazepam.Approved, Illicit
BrompheniramineThe risk or severity of adverse effects can be increased when Codeine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Codeine is combined with Brotizolam.Approved, Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Codeine is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Codeine.Approved, Investigational
BuprenorphineCodeine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe therapeutic efficacy of Codeine can be decreased when used in combination with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Codeine is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Codeine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Codeine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Codeine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Codeine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Codeine is combined with Butethal.Approved, Illicit
ButorphanolButorphanol may decrease the analgesic activities of Codeine.Approved, Illicit, Vet Approved
Canrenoic acidThe risk or severity of adverse effects can be increased when Codeine is combined with Canrenoic acid.Approved, Withdrawn
CanrenoneThe risk or severity of adverse effects can be increased when Codeine is combined with Canrenone.Investigational
CarbamazepineThe metabolism of Codeine can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Codeine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Codeine is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Codeine is combined with Carisoprodol.Approved
CelecoxibThe therapeutic efficacy of Codeine can be decreased when used in combination with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Codeine can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Codeine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Codeine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Codeine is combined with Chlordiazepoxide.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Codeine is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Codeine is combined with Chloroprocaine.Approved
ChloroquineThe therapeutic efficacy of Codeine can be decreased when used in combination with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Codeine is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Codeine is combined with Chlorphenamine.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Codeine.Withdrawn
ChlorphentermineChlorphentermine may increase the analgesic activities of Codeine.Illicit, Withdrawn
ChlorpromazineThe therapeutic efficacy of Codeine can be decreased when used in combination with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Codeine is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Codeine is combined with Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Codeine is combined with Chlorzoxazone.Approved
CholecalciferolThe therapeutic efficacy of Codeine can be decreased when used in combination with Cholecalciferol.Approved, Nutraceutical
CicletanineThe risk or severity of adverse effects can be increased when Codeine is combined with Cicletanine.Investigational
CimetidineThe therapeutic efficacy of Codeine can be decreased when used in combination with Cimetidine.Approved
CinacalcetThe therapeutic efficacy of Codeine can be decreased when used in combination with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Codeine is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe therapeutic efficacy of Codeine can be decreased when used in combination with Citalopram.Approved
ClarithromycinThe metabolism of Codeine can be decreased when combined with Clarithromycin.Approved
ClemastineThe therapeutic efficacy of Codeine can be decreased when used in combination with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Codeine is combined with Clidinium.Approved
ClobazamThe therapeutic efficacy of Codeine can be decreased when used in combination with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Codeine is combined with clomethiazole.Investigational
ClomipramineThe therapeutic efficacy of Codeine can be decreased when used in combination with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Codeine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Codeine is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Codeine is combined with Clorazepate.Approved, Illicit
ClotrimazoleThe therapeutic efficacy of Codeine can be decreased when used in combination with Clotrimazole.Approved, Vet Approved
ClozapineThe therapeutic efficacy of Codeine can be decreased when used in combination with Clozapine.Approved
CobicistatThe therapeutic efficacy of Codeine can be decreased when used in combination with Cobicistat.Approved
CocaineThe therapeutic efficacy of Codeine can be decreased when used in combination with Cocaine.Approved, Illicit
ConivaptanThe serum concentration of Codeine can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Codeine can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Codeine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Codeine is combined with Cyclobenzaprine.Approved
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Codeine.Approved
CyclosporineThe metabolism of Codeine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideThe risk or severity of adverse effects can be increased when Codeine is combined with Cyclothiazide.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Codeine is combined with Cyproheptadine.Approved
DabrafenibThe serum concentration of Codeine can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Codeine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Codeine.Approved
DapoxetineCodeine may increase the serotonergic activities of Dapoxetine.Investigational
DarifenacinThe therapeutic efficacy of Codeine can be decreased when used in combination with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Codeine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Codeine can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Codeine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe therapeutic efficacy of Codeine can be decreased when used in combination with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Codeine is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Codeine is combined with Desflurane.Approved
DesipramineThe therapeutic efficacy of Codeine can be decreased when used in combination with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Codeine is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Codeine is combined with Desmopressin.Approved
DesvenlafaxineCodeine may increase the serotonergic activities of Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Codeine is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Codeine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Codeine is combined with Dexbrompheniramine.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Codeine.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Codeine is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineDextroamphetamine may increase the analgesic activities of Codeine.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Codeine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Codeine is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Codeine is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Codeine is combined with Diazepam.Approved, Illicit, Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Codeine.Approved
DiethylpropionDiethylpropion may increase the analgesic activities of Codeine.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Codeine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe metabolism of Codeine can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Codeine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Codeine is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Codeine can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Codeine is combined with Dimenhydrinate.Approved
DiphenhydramineThe therapeutic efficacy of Codeine can be decreased when used in combination with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Codeine is combined with Diphenoxylate.Approved, Illicit
DoramectinThe risk or severity of adverse effects can be increased when Codeine is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Codeine is combined with Doxepin.Approved
DoxycyclineThe metabolism of Codeine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Codeine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Codeine is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Codeine.Approved, Illicit
DronedaroneThe therapeutic efficacy of Codeine can be decreased when used in combination with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Codeine.Approved, Vet Approved
DrospirenoneThe risk or severity of adverse effects can be increased when Codeine is combined with Drospirenone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Codeine is combined with Drotebanol.Experimental, Illicit
DuloxetineThe therapeutic efficacy of Codeine can be decreased when used in combination with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Codeine is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Codeine is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Codeine is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Codeine is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Codeine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Codeine is combined with Efonidipine.Approved
EliglustatThe therapeutic efficacy of Codeine can be decreased when used in combination with Eliglustat.Approved
EluxadolineCodeine may increase the constipating activities of Eluxadoline.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Codeine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Codeine is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Codeine can be decreased when it is combined with Enzalutamide.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Codeine is combined with Eplerenone.Approved
ErythromycinThe metabolism of Codeine can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramCodeine may increase the serotonergic activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Codeine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstazolamThe risk or severity of adverse effects can be increased when Codeine is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Codeine is combined with Eszopiclone.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Codeine is combined with Etacrynic acid.Approved
EthanolCodeine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Codeine.Approved, Illicit, Withdrawn
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Codeine.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Codeine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Codeine is combined with Ethotoin.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Codeine is combined with Ethoxzolamide.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Codeine is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Codeine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Codeine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Codeine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Codeine is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Codeine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Codeine.Approved
EtoperidoneCodeine may increase the serotonergic activities of Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Codeine is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Codeine can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Codeine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Codeine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Codeine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Codeine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Codeine.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Codeine is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Codeine is combined with Flibanserin.Approved
FluconazoleThe metabolism of Codeine can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Codeine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Codeine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Codeine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe therapeutic efficacy of Codeine can be decreased when used in combination with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Codeine is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Codeine is combined with Fluphenazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Codeine is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Codeine is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Codeine is combined with Fluticasone Propionate.Approved
FluvoxamineThe therapeutic efficacy of Codeine can be decreased when used in combination with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Codeine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Codeine can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Codeine can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Codeine is combined with Fospropofol.Approved, Illicit
FurosemideThe risk or severity of adverse effects can be increased when Codeine is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Codeine can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Codeine is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Codeine is combined with gabapentin enacarbil.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Codeine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Codeine is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Codeine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Codeine is combined with Glutethimide.Approved, Illicit
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Codeine.Approved, Investigational, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Codeine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Codeine is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe therapeutic efficacy of Codeine can be decreased when used in combination with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Codeine is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Codeine is combined with Heroin.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Codeine.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Codeine is combined with Hexobarbital.Approved
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Codeine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Codeine is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneCodeine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Codeine is combined with Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Codeine is combined with Hydromorphone.Approved, Illicit
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may increase the analgesic activities of Codeine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Codeine.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Codeine.Approved
IdelalisibThe serum concentration of Codeine can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Codeine is combined with Iloperidone.Approved
ImatinibThe metabolism of Codeine can be decreased when combined with Imatinib.Approved
ImipramineThe therapeutic efficacy of Codeine can be decreased when used in combination with Imipramine.Approved
IndalpineCodeine may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Codeine is combined with Indapamide.Approved
IndinavirThe therapeutic efficacy of Codeine can be decreased when used in combination with Indinavir.Approved
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Codeine.Approved
IsavuconazoniumThe metabolism of Codeine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Codeine is combined with Isoflurane.Approved, Vet Approved
IsoniazidThe therapeutic efficacy of Codeine can be decreased when used in combination with Isoniazid.Approved
IsosorbideThe risk or severity of adverse effects can be increased when Codeine is combined with Isosorbide.Approved
IsradipineThe metabolism of Codeine can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Codeine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Codeine can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Codeine is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Codeine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Codeine is combined with Ketobemidone.Approved
KetoconazoleThe therapeutic efficacy of Codeine can be decreased when used in combination with Ketoconazole.Approved, Investigational
KW-3902The risk or severity of adverse effects can be increased when Codeine is combined with KW-3902.Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Codeine is combined with Lamotrigine.Approved, Investigational
LanreotideThe metabolism of Codeine can be decreased when combined with Lanreotide.Approved
LevetiracetamThe risk or severity of adverse effects can be increased when Codeine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Codeine is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Codeine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Codeine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Codeine is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Codeine is combined with Levomethadyl Acetate.Approved
LevomilnacipranCodeine may increase the serotonergic activities of Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Codeine is combined with Levorphanol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Codeine.Approved, Vet Approved
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Codeine.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Codeine is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Codeine is combined with Lofentanil.Illicit
LopinavirThe therapeutic efficacy of Codeine can be decreased when used in combination with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Codeine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Codeine.Approved
LorcaserinThe therapeutic efficacy of Codeine can be decreased when used in combination with Lorcaserin.Approved
LovastatinThe metabolism of Codeine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Codeine is combined with Loxapine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Codeine is combined with Lu AA21004.Investigational
LuliconazoleThe serum concentration of Codeine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Codeine can be increased when combined with Lumacaftor.Approved
LumefantrineThe therapeutic efficacy of Codeine can be decreased when used in combination with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Codeine is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Codeine.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Codeine is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Codeine is combined with Maprotiline.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Codeine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Codeine is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Codeine is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Codeine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Codeine is combined with Melperone.Approved
MephedroneMephedrone may increase the analgesic activities of Codeine.Investigational
MephentermineMephentermine may increase the analgesic activities of Codeine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Codeine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Codeine is combined with Meprobamate.Approved, Illicit
MersalylThe risk or severity of adverse effects can be increased when Codeine is combined with Mersalyl.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Codeine is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Codeine is combined with Metaxalone.Approved
MethadoneThe therapeutic efficacy of Codeine can be decreased when used in combination with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Codeine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineMethamphetamine may increase the analgesic activities of Codeine.Approved, Illicit
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Codeine.Approved
MethapyrileneThe risk or severity of adverse effects can be increased when Codeine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Codeine is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Codeine is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Codeine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Codeine is combined with Methohexital.Approved
MethotrimeprazineCodeine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Codeine is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Codeine is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Codeine is combined with Methyclothiazide.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Codeine.Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Codeine is combined with Methylphenobarbital.Approved
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Codeine.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Codeine is combined with Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Codeine.Approved, Investigational
MetyrosineCodeine may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Codeine is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Codeine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranCodeine may increase the serotonergic activities of Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Codeine.Approved, Investigational
MirabegronThe therapeutic efficacy of Codeine can be decreased when used in combination with Mirabegron.Approved
MirtazapineCodeine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Codeine can be decreased when it is combined with Mitotane.Approved
MMDAMMDA may increase the analgesic activities of Codeine.Experimental, Illicit
ModafinilThe serum concentration of Codeine can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Codeine is combined with Molindone.Approved
MoricizineMoricizine may increase the hypotensive activities of Codeine.Approved, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Codeine.Approved, Investigational
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Codeine.Vet Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Codeine.Approved, Investigational
NafcillinThe serum concentration of Codeine can be decreased when it is combined with Nafcillin.Approved
NalbuphineNalbuphine may decrease the analgesic activities of Codeine.Approved
NaltrexoneThe therapeutic efficacy of Codeine can be decreased when used in combination with Naltrexone.Approved, Investigational, Vet Approved
NefazodoneThe metabolism of Codeine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Codeine can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Codeine can be increased when it is combined with Netupitant.Approved
NevirapineThe therapeutic efficacy of Codeine can be decreased when used in combination with Nevirapine.Approved
NicardipineThe therapeutic efficacy of Codeine can be decreased when used in combination with Nicardipine.Approved
NilotinibThe therapeutic efficacy of Codeine can be decreased when used in combination with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Codeine is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Codeine is combined with Nitrous oxide.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Codeine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Codeine is combined with Nortriptyline.Approved
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Codeine.Investigational
OctreotideThe metabolism of Codeine can be decreased when combined with Octreotide.Approved, Investigational
OlanzapineThe risk or severity of adverse effects can be increased when Codeine is combined with Olanzapine.Approved, Investigational
OlaparibThe metabolism of Codeine can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Codeine is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Codeine is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Codeine is combined with Opium.Approved, Illicit
OrphenadrineCodeine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Codeine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Codeine can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Codeine is combined with Oxazepam.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Codeine is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Codeine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Codeine is combined with Oxybuprocaine.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Codeine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Codeine is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Codeine is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Codeine.Approved
PalbociclibThe serum concentration of Codeine can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Codeine is combined with Paliperidone.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Codeine.Approved
PanobinostatThe serum concentration of Codeine can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeCodeine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe therapeutic efficacy of Codeine can be decreased when used in combination with Paroxetine.Approved, Investigational
PasireotideThe metabolism of Codeine can be decreased when combined with Pasireotide.Approved
Peginterferon alfa-2bThe serum concentration of Codeine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Codeine.Approved
PentazocinePentazocine may decrease the analgesic activities of Codeine.Approved, Vet Approved
PentobarbitalThe metabolism of Codeine can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Codeine.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Codeine.Approved
PerazineThe risk or severity of adverse effects can be increased when Codeine is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Codeine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Codeine is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Codeine is combined with Pethidine.Approved
PhenobarbitalThe metabolism of Codeine can be increased when combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Codeine is combined with Phenoxyethanol.Approved
PhenterminePhentermine may increase the analgesic activities of Codeine.Approved, Illicit
PhenytoinThe metabolism of Codeine can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Codeine is combined with Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Codeine is combined with Pipamperone.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Codeine.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Codeine is combined with Pipotiazine.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Codeine.Approved
PiretanideThe risk or severity of adverse effects can be increased when Codeine is combined with Piretanide.Experimental
PiritramideThe risk or severity of adverse effects can be increased when Codeine is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Codeine is combined with Pizotifen.Approved
PolythiazideThe risk or severity of adverse effects can be increased when Codeine is combined with Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Codeine is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Codeine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PotassiumThe risk or severity of adverse effects can be increased when Codeine is combined with Potassium.Approved
Potassium CitrateThe risk or severity of adverse effects can be increased when Codeine is combined with Potassium Citrate.Approved, Vet Approved
PramipexoleCodeine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Codeine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Codeine is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Codeine.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Codeine is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Codeine is combined with Prilocaine.Approved
PrimidoneThe metabolism of Codeine can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Codeine is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Codeine is combined with Prochlorperazine.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Codeine.Approved
PromazineThe therapeutic efficacy of Codeine can be decreased when used in combination with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Codeine is combined with Promethazine.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Codeine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Codeine is combined with Proparacaine.Approved, Vet Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Codeine.Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Codeine.Investigational
PropofolThe risk or severity of adverse effects can be increased when Codeine is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Codeine is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Codeine is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when Codeine is combined with PSD502.Investigational
PseudoephedrinePseudoephedrine may increase the analgesic activities of Codeine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Codeine is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Codeine is combined with Quetiapine.Approved
QuinethazoneThe risk or severity of adverse effects can be increased when Codeine is combined with Quinethazone.Approved
QuinidineThe therapeutic efficacy of Codeine can be decreased when used in combination with Quinidine.Approved
QuinineThe therapeutic efficacy of Codeine can be decreased when used in combination with Quinine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Codeine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Codeine is combined with Ramelteon.Approved, Investigational
RamosetronCodeine may increase the constipating activities of Ramosetron.Approved
RanolazineThe therapeutic efficacy of Codeine can be decreased when used in combination with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Codeine is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Codeine is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Codeine.Approved
RifabutinThe metabolism of Codeine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Codeine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Codeine can be increased when combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Codeine is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Codeine is combined with Ritanserin.Investigational
RitobegronRitobegron may increase the analgesic activities of Codeine.Investigational
RitonavirThe therapeutic efficacy of Codeine can be decreased when used in combination with Ritonavir.Approved, Investigational
RolapitantThe therapeutic efficacy of Codeine can be decreased when used in combination with Rolapitant.Approved
RolofyllineThe risk or severity of adverse effects can be increased when Codeine is combined with Rolofylline.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Codeine is combined with Romifidine.Vet Approved
RopiniroleThe therapeutic efficacy of Codeine can be decreased when used in combination with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Codeine.Approved
RotigotineCodeine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Codeine.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Codeine is combined with S-Ethylisothiourea.Experimental
Sage 547The risk or severity of adverse effects can be increased when Codeine is combined with Sage 547.Investigational
SaquinavirThe metabolism of Codeine can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Codeine is combined with Scopolamine.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Codeine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Codeine is combined with Secobarbital.Approved, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Codeine is combined with Sertindole.Approved, Withdrawn
SertralineThe therapeutic efficacy of Codeine can be decreased when used in combination with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Codeine is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Codeine can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Codeine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Codeine can be increased when it is combined with Simeprevir.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Codeine.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Codeine.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Codeine is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Codeine can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Codeine can be increased when it is combined with Stiripentol.Approved
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Codeine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Codeine is combined with Sufentanil.Approved, Investigational
SulfisoxazoleThe metabolism of Codeine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Codeine is combined with Sulpiride.Approved
SuvorexantCodeine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Codeine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Codeine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Codeine is combined with Tasimelteon.Approved
TelaprevirThe metabolism of Codeine can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Codeine can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Codeine.Approved
TerbinafineThe therapeutic efficacy of Codeine can be decreased when used in combination with Terbinafine.Approved, Investigational, Vet Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Codeine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Codeine is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Codeine is combined with Tetrodotoxin.Investigational
ThalidomideCodeine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineThe risk or severity of adverse effects can be increased when Codeine is combined with Theobromine.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Codeine is combined with Thiamylal.Approved, Vet Approved
ThiethylperazineThiethylperazine may increase the hypotensive activities of Codeine.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Codeine is combined with Thiopental.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Codeine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Codeine is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Codeine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Codeine is combined with Tiapride.Investigational
TiclopidineThe therapeutic efficacy of Codeine can be decreased when used in combination with Ticlopidine.Approved
TicrynafenThe risk or severity of adverse effects can be increased when Codeine is combined with Ticrynafen.Withdrawn
TiletamineThe risk or severity of adverse effects can be increased when Codeine is combined with Tiletamine.Vet Approved
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Codeine.Approved
TipranavirThe therapeutic efficacy of Codeine can be decreased when used in combination with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Codeine is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Codeine can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Codeine is combined with Tolcapone.Approved, Withdrawn
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Codeine.Approved, Investigational
TolvaptanThe risk or severity of adverse effects can be increased when Codeine is combined with Tolvaptan.Approved
TopiramateThe risk or severity of adverse effects can be increased when Codeine is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Codeine is combined with Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Codeine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Codeine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe therapeutic efficacy of Codeine can be decreased when used in combination with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Codeine is combined with Trazodone.Approved, Investigational
TriamtereneThe risk or severity of adverse effects can be increased when Codeine is combined with Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Codeine is combined with Triazolam.Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Codeine is combined with Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Codeine is combined with Trifluoperazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Codeine is combined with Triflupromazine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Codeine.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Codeine.Approved
TrimipramineThe risk or severity of adverse effects can be increased when Codeine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Codeine is combined with Triprolidine.Approved
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Codeine.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Codeine.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Codeine.Approved
Uc1010The risk or severity of adverse effects can be increased when Codeine is combined with Uc1010.Investigational
UlaritideThe risk or severity of adverse effects can be increased when Codeine is combined with Ularitide.Investigational
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Codeine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Codeine.Approved, Investigational
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Codeine.Approved
VenlafaxineThe therapeutic efficacy of Codeine can be decreased when used in combination with Venlafaxine.Approved
VerapamilThe metabolism of Codeine can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Codeine is combined with Vigabatrin.Approved
VoriconazoleThe metabolism of Codeine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Codeine is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Codeine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Codeine is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Codeine is combined with Ziconotide.Approved
ZimelidineCodeine may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe therapeutic efficacy of Codeine can be decreased when used in combination with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Codeine is combined with Zolazepam.Vet Approved
ZolpidemCodeine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Codeine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Codeine is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Codeine is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Codeine is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take with food, food reduces irritation.
  • To avoid constipation: increase your daily intake of fiber (beans, whole grains, vegetables).
References
Synthesis Reference

Nagaraj R. Ayyangar, Anil R. Choudhary, Uttam R. Kalkote, Vasant K. Sharma, “Process for the preparation of codeine from morphine.” U.S. Patent US4764615, issued May, 1912.

US4764615
General References
  1. Schroeder K, Fahey T: Over-the-counter medications for acute cough in children and adults in ambulatory settings. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD001831. [PubMed:15495019 ]
  2. Vree TB, van Dongen RT, Koopman-Kimenai PM: Codeine analgesia is due to codeine-6-glucuronide, not morphine. Int J Clin Pract. 2000 Jul-Aug;54(6):395-8. [PubMed:11092114 ]
  3. Srinivasan V, Wielbo D, Tebbett IR: Analgesic effects of codeine-6-glucuronide after intravenous administration. Eur J Pain. 1997;1(3):185-90. [PubMed:15102399 ]
External Links
ATC CodesN02AA59N02AA79R05DA04
AHFS Codes
  • 28:08.08
  • 48:08.00
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (52.5 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9966
Blood Brain Barrier+0.9979
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.8631
P-glycoprotein inhibitor IInhibitor0.5435
P-glycoprotein inhibitor IINon-inhibitor0.8724
Renal organic cation transporterInhibitor0.638
CYP450 2C9 substrateNon-substrate0.7698
CYP450 2D6 substrateSubstrate0.9274
CYP450 3A4 substrateSubstrate0.7796
CYP450 1A2 substrateNon-inhibitor0.6494
CYP450 2C9 inhibitorNon-inhibitor0.8866
CYP450 2D6 inhibitorInhibitor0.6978
CYP450 2C19 inhibitorNon-inhibitor0.8256
CYP450 3A4 inhibitorNon-inhibitor0.8899
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.747
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.9567
BiodegradationNot ready biodegradable0.9935
Rat acute toxicity2.8450 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8556
hERG inhibition (predictor II)Non-inhibitor0.8615
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Roxane laboratories inc
Packagers
Dosage forms
FormRouteStrength
SolutionOral
TabletOral300 mg/1
CapsuleOral
TabletOral
LiquidOral
Tablet, extended releaseOral
Tablet, extended releaseOral100 mg
Tablet, extended releaseOral150 mg
Tablet, extended releaseOral200 mg
Tablet, extended releaseOral50 mg
SolutionIntramuscular; Subcutaneous30 mg
SolutionIntramuscular; Subcutaneous60 mg
LiquidIntramuscular; Subcutaneous30 mg
SyrupOral5.0 mg
TabletOral60 mg
SolutionOral15 mg/2.5mL
SolutionOral30 mg/5mL
TabletOral15 mg/1
TabletOral30 mg/1
TabletOral60 mg/1
LiquidOral.2 %
LiquidOral10 mg
ElixirOral
SyrupOral
SyrupOral5 mg
TabletOral15 mg
TabletOral30 mg
KitOral
SuspensionOral
Prices
Unit descriptionCostUnit
Codeine phosphate powder8.25USD g
Codeine Phosphate 30 mg/ml1.31USD ml
Codeine sulfate 60 mg tablet0.86USD tablet
Codeine sulfate 30 mg tablet0.76USD tablet
Codeine ph 30 mg/ml syringe0.54USD ml
Codeine ph 15 mg/ml syringe0.49USD ml
Codeine sulfate 15 mg tablet0.43USD tablet
Ratio-Codeine 30 mg Tablet0.09USD tablet
Ratio-Codeine 15 mg Tablet0.07USD tablet
Ratio-Codeine 5 mg/ml Syrup0.03USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6248363 No1999-11-232019-11-23Us
US6383471 No1999-04-062019-04-06Us
US9066942 No2012-01-032032-01-03Us
US9107921 No2012-01-032032-01-03Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point157.5 °CPhysProp
boiling point250 °C at 2.20E+01 mm HgPhysProp
water solubility9000 mg/L (at 20 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.19AVDEEF,A ET AL. (1996)
logS-1.52ADME Research, USCD
pKa8.21 (at 25 °C)LIDE,DR (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.577 mg/mLALOGPS
logP1.2ALOGPS
logP1.34ChemAxon
logS-2.7ALOGPS
pKa (Strongest Acidic)13.78ChemAxon
pKa (Strongest Basic)9.19ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area41.93 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity84.6 m3·mol-1ChemAxon
Polarizability31.95 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL Thermo Scientific) 60V, Positivesplash10-0uxr-0973000000-87d07ddd2ed24b9598d7View in MoNA
MSMass Spectrum (Electron Ionization)splash10-01ot-3950000000-e80ecb11646b4da6aa92View in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassMorphinans
Sub ClassNot Available
Direct ParentMorphinans
Alternative Parents
Substituents
  • Morphinan
  • Benzylisoquinoline
  • Phenanthrene
  • Tetralin
  • Benzofuran
  • Anisole
  • Aralkylamine
  • Alkyl aryl ether
  • Benzenoid
  • Piperidine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary alcohol
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
partial agonist
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Molecular Weight:
44778.855 Da
References
  1. Grond S, Sablotzki A: Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879-923. [PubMed:15509185 ]
  2. Takahama K, Shirasaki T: Central and peripheral mechanisms of narcotic antitussives: codeine-sensitive and -resistant coughs. Cough. 2007 Jul 9;3:8. [PubMed:17620111 ]
  3. Freissmuth M, Beindl W, Kratzel M: Binding and structure-activity-relation of benzo[f]isoquinoline- and norcodeinone-derivatives at mu-opioid receptors in the rat cerebral cortex. Br J Pharmacol. 1993 Dec;110(4):1429-36. [PubMed:8306082 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
partial agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates th...
Gene Name:
OPRK1
Uniprot ID:
P41145
Molecular Weight:
42644.665 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Takahama K, Shirasaki T: Central and peripheral mechanisms of narcotic antitussives: codeine-sensitive and -resistant coughs. Cough. 2007 Jul 9;3:8. [PubMed:17620111 ]
  4. Mignat C, Wille U, Ziegler A: Affinity profiles of morphine, codeine, dihydrocodeine and their glucuronides at opioid receptor subtypes. Life Sci. 1995;56(10):793-9. [PubMed:7885194 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurot...
Gene Name:
OPRD1
Uniprot ID:
P41143
Molecular Weight:
40368.235 Da
References
  1. Ortiz MI, Castro-Olguin J, Pena-Samaniego N, Castaneda-Hernandez G: Probable activation of the opioid receptor-nitric oxide-cyclic GMP-K+ channels pathway by codeine. Pharmacol Biochem Behav. 2005 Dec;82(4):695-703. Epub 2006 Jan 4. [PubMed:16386786 ]
  2. Mignat C, Wille U, Ziegler A: Affinity profiles of morphine, codeine, dihydrocodeine and their glucuronides at opioid receptor subtypes. Life Sci. 1995;56(10):793-9. [PubMed:7885194 ]
  3. Loghin F, Popa DS, Socaciu C: Influence of glutethimide on rat brain mononucleotides by sub-chronic codeine treatment. J Cell Mol Med. 2001 Oct-Dec;5(4):409-16. [PubMed:12067475 ]
  4. Advenier C, Girard V, Naline E, Vilain P, Emonds-Alt X: Antitussive effect of SR 48968, a non-peptide tachykinin NK2 receptor antagonist. Eur J Pharmacol. 1993 Nov 30;250(1):169-71. [PubMed:8119316 ]
  5. Karlsson JA, Lanner AS, Persson CG: Airway opioid receptors mediate inhibition of cough and reflex bronchoconstriction in guinea pigs. J Pharmacol Exp Ther. 1990 Feb;252(2):863-8. [PubMed:2156065 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Zhou SF: Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet. 2009;48(11):689-723. doi: 10.2165/11318030-000000000-00000. [PubMed:19817501 ]
  2. Duquette PH, Peterson FJ, Crankshaw DL, Lindemann NJ, Holtzman JL: Studies of the metabolic N- and O-demethylation of [6-3H]codeine. Drug Metab Dispos. 1983 Sep-Oct;11(5):477-80. [PubMed:6138234 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Duquette PH, Peterson FJ, Crankshaw DL, Lindemann NJ, Holtzman JL: Studies of the metabolic N- and O-demethylation of [6-3H]codeine. Drug Metab Dispos. 1983 Sep-Oct;11(5):477-80. [PubMed:6138234 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Glucuronosyltransferase activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol suggests it may play an important role in regulating the level and activity of these potent and active estrogen metabolites. Is also active with androsterone, hyodeoxycholic acid and tetrachlorocatechol...
Gene Name:
UGT2B7
Uniprot ID:
P16662
Molecular Weight:
60694.12 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Glucuronosyltransferase activity
Specific Function:
UDPGTs are of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isozyme is active on polyhydroxylated estrogens (such as estriol, 4-hydroxyestrone and 2-hydroxyestriol) and xenobiotics (such as 4-methylumbelliferone, 1-naphthol, 4-nitrophenol, 2-aminophenol, 4-hydroxybiphenyl and menthol). It is capable of 6 alpha-hydr...
Gene Name:
UGT2B4
Uniprot ID:
P06133
Molecular Weight:
60512.035 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Secondary active organic cation transmembrane transporter activity
Specific Function:
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:
SLC22A1
Uniprot ID:
O15245
Molecular Weight:
61153.345 Da
References
  1. Tzvetkov MV, dos Santos Pereira JN, Meineke I, Saadatmand AR, Stingl JC, Brockmoller J: Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. Biochem Pharmacol. 2013 Sep 1;86(5):666-78. doi: 10.1016/j.bcp.2013.06.019. Epub 2013 Jul 5. [PubMed:23835420 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 09, 2016 02:40